CTXR has 36-month beta value of 1.65. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTXR is 168.41M, and currently, short sellers hold a 8.68% ratio of that float. The average trading volume of CTXR on August 19, 2024 was 2.62M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTXR) stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR)’s stock price has soared by 7.31 in relation to previous closing price of 0.60. Nevertheless, the company has seen a loss of -6.37% in its stock price over the last five trading days. prnewswire.com reported 2024-08-12 that Granted FDA approval of LYMPHIR™ for the treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidiary with TenX Keane; Citius Oncology expected to begin trading on Nasdaq on August 13, 2024, under ticker CTOR Achieved primary and secondary endpoints of Mino-Lok® Phase 3 Trial CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter 2024 ended June 30, 2024.
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has experienced a -6.37% fall in stock performance for the past week, with a -18.26% drop in the past month, and a -0.19% drop in the past quarter. The volatility ratio for the week is 12.11%, and the volatility levels for the past 30 days are at 13.15% for CTXR. The simple moving average for the last 20 days is -23.15% for CTXR’s stock, with a simple moving average of -13.14% for the last 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at -11.40% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.51% of loss for the given period.
Volatility was left at 13.15%, however, over the last 30 days, the volatility rate increased by 12.11%, as shares sank -23.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.85% upper at present.
During the last 5 trading sessions, CTXR fell by -5.09%, which changed the moving average for the period of 200-days by -12.84% in comparison to the 20-day moving average, which settled at $0.8324. In addition, Citius Pharmaceuticals Inc saw -14.45% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTXR
The total capital return value is set at -0.44. Equity return is now at value -41.76, with -36.91 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -90.9. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -10.01.
Currently, EBITDA for the company is -36.54 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.75.
Conclusion
To put it simply, Citius Pharmaceuticals Inc (CTXR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
